title: Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.
abstract: Much has been learned since the discovery of KSHV in 1994 about its epidemiology and pathology but much of what has been learned has yet to be translated into clinical practice. In this review, we survey the current state of knowledge on KSHV epidemiology and KS pathogenesis and highlight therapeutic opportunities in both the developed and developing world.
authors.affiliation: HIV and AIDS Malignancy Branch, National Cancer Institute/NIH, Bethesda, MD 20892, USA. uldrickts@mail.nih.gov
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Uldrick
authors.forename: Denise
authors.initials: D
authors.lastname: Whitby
mesh_terms: D000818:Animals; D044966:Anti-Retroviral Agents / Q000494:pharmacology; D015658:HIV Infections / Q000150:complications; D019288:Herpesvirus 8, Human / Q000378:metabolism*; D006801:Humans; D007107:Immune System; D007249:Inflammation; D051379:Mice; D015995:Prevalence; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000453:epidemiology / Q000628:therapy* / Q000821:virology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014779:Virus Replication
chemical_list: D044966:Anti-Retroviral Agents; D042461:Vascular Endothelial Growth Factor A